A 67-year-old Italian woman has regained her sight after doctors performed an unprecedented macula and retina transplant [1].
This procedure represents a potential breakthrough in ophthalmology, as it demonstrates the possibility of restoring vision by relocating functional retinal tissue within the same patient. The success of the surgery could open new avenues for treating severe macular degeneration and other forms of permanent blindness.
The patient had been blind for five years prior to the surgery [2]. To address the loss of vision, surgeons performed a procedure that moved healthy retinal tissue from the patient's blind left eye to her right eye [1], [4]. This technique allowed the medical team to utilize the patient's own biological material to restore sight.
Medical reports said that this is the first macula transplant of its kind recorded in Italy [3]. The operation took place at a hospital in Italy earlier this year, with the results publicized on July 28 [1], [2].
While most sources describe the transplant as involving the macula and retina [1], [4], some reporting contains contradictions regarding the specific ocular tissues used. One report suggests the cornea and sclera were transplanted [5], but the primary consensus among the medical reports emphasizes the relocation of retinal tissue to restore the central vision functions of the macula.
The surgery targeted the macula, the small central area of the retina responsible for sharp, detailed vision. By transplanting functional tissue from the non-seeing eye, surgeons aimed to bypass the damaged areas of the right eye and restore a connection between the retina and the optic nerve [1], [6].
“A 67-year-old Italian woman has regained her sight after doctors performed an unprecedented macula and retina transplant.”
This successful transplant suggests that autologous tissue transfer—using a patient's own cells—may be a viable solution for restoring vision in cases where traditional treatments fail. Because the tissue came from the patient herself, the risk of organ rejection is significantly reduced compared to donor transplants. If this method proves scalable, it could change the prognosis for patients with end-stage macular degeneration who previously had no hope of recovering their sight.
